It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Phreesia Inc. (PHR) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $32.36. The Phreesia Inc. has recorded 14,863 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Phreesia Announces Third Quarter Fiscal 2023 Results.
Phreesia Inc. is listed on the NYSE in the Healthcare sector while operating in the Health Information Services industry. At the end of the last regular session, the stock closed at $32.36 and fluctuated between $33.28 as its day high and $31.85 as its day low. The current market capitalization of Phreesia Inc. is $1.76B. A total of 0.38 million shares were traded on the day, compared to an average of 315.84K shares.
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, PHR has seen 3 BUY and 17 SELL insider trades, representing the acquisition of 1,098 and the disposition of 87,213 shares. Over the last 12 months, there were 49 BUYs and 75 SELLs from insiders. Insiders purchased 758,795 shares during that period but sold 258,013.
In the most recent transaction, VanDuyn Amy Beth sold 378 shares of PHR for 33.73 per share on Dec 20. After the transaction, the SVP, Human Resources now owns 87,049 company shares. In a previous transaction on Dec 14, Hoffman Allison C sold 801 shares at 36.00 per share. PHR shares that General Counsel & Secretary owns now total 102,262.
Among the insiders who sold shares, Hoffman Allison C disposed of 3,109 shares on Dec 13 at a per-share price of $34.40. This resulted in the General Counsel & Secretary holding 103,063 shares of PHR after the transaction. In another insider transaction, Linetsky David sold 11,377 shares at $34.61 per share on Dec 13. Company shares held by the SVP, Life Sciences now total 185,485.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for PHR in the last 3 months, the mean price target is $35.71 with high estimates of $41.00 and low estimates of $26.00. In terms of 52-week highs and lows, PHR has a high of $43.74 and a low of $13.19.
As of this writing, PHR has an earnings estimate of -$0.64 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.59 per share and a lower estimate of -$0.88. The company reported an EPS of -$0.71 in the last quarter, which was 25.30% higher than expectations of -$0.95.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 15 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PHR is Underweight with a score of 4.64. A total of 11 analysts rated the stock as Buy while 2 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.